Lupin has received approval from the US Food and Drug Administration for Eslicarbazepine Acetate Tablets, used for treating partial-onset seizures. The company’s latest pharmaceutical offering will help in managing this specific type of seizure disorder. Lupin’s achievement signifies another milestone in its commitment to providing effective treatments for various medical conditions. Additionally, the company’s use of cookies for analytics and advertising purposes is disclosed, ensuring transparency in data usage for visitors on their website. Lupin’s continued dedication to innovation and regulatory compliance demonstrates its position as a leading pharmaceutical company in the industry.
Source link
Lupin bags USFDA nod for Eslicarbazepine Acetate Tablets for partial-onset seizures
